SpondyloarthropathiesArchives
The VITACORA- 19 and PsAID questionnaires are equally valid for assessing the impact of psoriatic arthritis on patients' quality of life
Spondyloarthropathies 5 min.
Psoriatic arthritis (PsA) is a multi-domain disease in which musculoskeletal and cutaneous manifestations converge to varying degrees. All these aspects need to be considered when addressing disease activity and the overall impact of the disease on the lives of people with PsA [1,2,3,4,5]. However, instruments...
Prevalence and factors associated with fatigue in patients with psoriatic arthritis: a systematic review and meta-analysis
Spondyloarthropathies 5 min.
Psoriatic arthritis (PsA) is a systemic inflammatory condition characterised by a high degree of heterogeneity. Beyond articular manifestations, patients also have extensive extra-articular manifestations, such as ocular and dermal involvement [1, 2–3]. Patients diagnosed with PsA also have other...
Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies
Spondyloarthropathies 7 min.
Data are available on reasonable request. Underlying data from this manuscript may be requested by qualified researchers 6 months after product approval in the USA and/or Europe, or global development is discontinued, and 18 months after study completion. Investigators may request access to anonymised...
The insula represents a key neurobiological pain hub in psoriatic arthritis
Spondyloarthropathies 5 min.
Psoriatic arthritis (PsA) is a chronic immune-mediated disease characterised by painful articular and peri-articular musculoskeletal inflammation. Pain represents a major burden in this population, impacting quality of life and daily function [1]. The currently available immunotherapies offer comprehensive...
